

AddLife signed an agreement for acquiring Euroclone S.p.A.

Today, AddLife signed an agreement to acquire all shares of the Italian company Euroclone S.p.A. which is a leading supplier of instruments and consumables in the field of cell and molecular biology in Italy. The acquisition represents AddLife's entry into the Italian market in a segment in which the company is already an established supplier in the Nordic market. AddLife already conducts business in Italy in the Medtech business area.

Euroclone markets and sells a broad portfolio of both market-leading brands and proprietary brands in the field of cell and molecular biology and, with niche products, also in the Medtech business area. The company's end customers are primarily hospital laboratories, research centres, private clinics and industrial centres in Italy.

Euroclone has distribution rights in Italy for some of AddLife's current suppliers in the Nordic countries, which further strengthens AddLife's position on the European market.

Euroclone is headquartered in Milan and engages in sales through its own sales resources, as well as through regional agents. The company currently has 58 employees and sales of EUR 27 million in the Italian market.

"The acquisition expands our geographic market in an interesting market segment in which we are already a well-established supplier in the Nordic region, while further strengthening our long-term business relationships with a number of suppliers that Euroclone also represents," says Peter Simonsbacka, Business Area Manager, LabTech, AddLife AB.

Franco Aiolfi, CEO of Euroclone, highly positively values the acquisition of Euroclone's shares by AddLife AB in the light of ensuring continuity and further expansion of the company in the Italian market and in the export of the proprietary private lines.

"For AddLife AB's philosophy, continuity and independency of the companies they buy are the foundations of their project of territorial expansion. This, together with their particular attention to the existing Human Resources, made AddLife AB the right partner I was looking for" states Franco Aiolfi, CEO of Euroclone SpA.

Franco Aiolfi will serve as CEO of the company for at least the next two years to ensure smooth hand-over of the business to the total success of this operation to the benefit of AddLife, Euroclone's employees and suppliers.

The deal is expected to close in January 2020.

Milan/Stockholm – November 28th, 2019

AddLife is an independent player in Life Science that offers high-quality products, services and advice to both the private and public sector, mainly in the Nordic region and the rest of Europe. AddLife has about 900 employees in some 40 subsidiaries that operate under their own brands. The Group has annual sales of about SEK 3.1 billion. AddLife shares are listed on NASDAQ Stockholm.

This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10:00 a.m. (CET) on 28 November 2019.